For instance, the STORI trial—a multicenter prospective study assessing relapse risk after withdrawing maintenance anti-TNF in Crohn’s disease (excluding perianal disease)—found relapse rates of 43.9% at 12 months and 52.2% at 24 months, with a median time to relapse of 16.4 months [8]. This evidence concerns the gene TNF and Crohn disease.